Krónikus limfoid leukémia (CLL): vizsgálatok itt: Dánia
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Aarhus N, Copenhagen Oe, Odense C
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Aarhus N, Odense C
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Aalborg, Aarhus N, Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Aalborg, Aarhus N, Koege, Odense C
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Aalborg, Copenhagen Oe, Odense C, Roskilde
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Copenhagen, Roskilde, Vejle
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Aalborg, Odense C, Roskilde
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - 2. fázisNot yet taking people in DániaTreatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.
- Where
- Copenhagen
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07860775 · EU 2025-524842-89-00 - 1/2. fázisTaking peopleVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Where
- Aalborg, Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 112 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00 - 3. fázisTaking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Aarhus N, Copenhagen Oe, Koege, Odense C, Vejle
- Életkor
- 18 év and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- København Ø
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 2. fázisTaking peopleREtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
- Where
- Aarhus N
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT04523428 · EU 2023-505449-18-00